Omzet 2024 * | 101 mln. 94,14 mln. | Omzet 2025 * | 113 mln. 105 mln. | Marktkapitalisatie | 195 mln. 181 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -17 mln. -15,79 mln. | Nettowinst (verlies) 2025 * | -12 mln. -11,15 mln. | EV/omzet 2024 * | 1,92 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 1,72 x |
K/w-verhouding 2024 * |
-11,5
x | K/w-verhouding 2025 * |
-20
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 79,96% |
Recentste transcriptie over OptimizeRx Corporation
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Will Febbo
CEO | Chief Executive Officer | 55 | 22-02-16 |
Edward Stelmakh
DFI | Director of Finance/CFO | 58 | 11-10-21 |
President | 46 | 29-04-19 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Gregory Wasson
BRD | Director/Board Member | 65 | 21-07-20 |
Catherine Klema
BRD | Director/Board Member | 65 | 24/01 |
Patrick Spangler
BRD | Director/Board Member | 68 | 27-03-18 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+24,11% | 429 mld. | |
+18,08% | 244 mld. | |
+18,87% | 101 mld. | |
+23,29% | 86,69 mld. | |
+57,98% | 58,56 mld. | |
+16,10% | 46,74 mld. | |
+3,99% | 36,65 mld. | |
+15,33% | 35,13 mld. | |
+8,88% | 27,67 mld. |